Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
EMERYVILLE, Calif., Feb. 27, 2018 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2017, after the market close, and will host a corporate update conference call and webcast on Tuesday, March 6, 2018, at 4:30 PM Eastern Time.
| Conference Call Details | |||||||
| Tuesday, March 6th @ 4:30 PM Eastern Time/1:30 PM Pacific Time | |||||||
| Toll Free: | 800-239-9838 | ||||||
| International: | 323-794-2551 | ||||||
| Conference ID: | 5092266 | ||||||
| Webcast: | http://public.viavid.com/index.php?id=128365 | ||||||
| Replays, available through March 20: | |||||||
| Domestic: | 844-512-2921 | ||||||
| International: | 412-317-6671 | ||||||
| Replay PIN: | 5092266 | ||||||
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT:
Investors: Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987 | [email protected]
